GLIOBLASTOMA: NEW THERAPEUTIC FRONTIERS BETWEEN NANOTECHNOLOGY, STEM CELLS, AND THE IMMUNE SYSTEM

Next week will be packed with events to disseminate information on the treatment of glioblastoma and high-grade brain tumors. As a reminder of our Tuesday evening video conference at 6:00 PM, titled PNEI AND TUMORS: THE HUMAN BODY’S ANTI-CANCER MOLECULES, I’m announcing a very interesting online webinar to be held next Wednesday, February 18, 2026, at 2:00 PM.

The webinar serves as the final moment and opportunity to share the results of the PRIN 2022 research project “PRECISE” (APtameR-based thEragnostiC strategy to impair the crosstalk between glioblastoma Stem cells and their niche). Funded by the Ministry of University and Research in 2023, the project involved a consortium of excellence composed of three prestigious Italian research groups:

• The CNR Unit in Naples (IEOMI-CNR), coordinated by Dr. Cristina Quintavalle, focused on the study of aptamers (short DNA/RNA sequences) to interfere with glioblastoma stem cells.
• The Polytechnic University of Turin Unit, led by Professor Alessandro Chiadò, dedicated to the development of advanced nanotechnologies to identify and selectively target tumor cells.
• The Sapienza University of Rome Unit, under the direction of Professor Aurelia Rughetti, focused on analyzing the immune response in glioblastoma and disseminating the results.

The goal of the meeting is to translate the complex language of research into knowledge accessible to all. The webinar is aimed not only at professionals, but also at patients, families, students, and anyone interested in scientific topics that have such a profound impact on healthcare and social life.

The “new frontiers” where technology and biology are combined in an effort to break down glioblastoma’s resistance, aiming for increasingly targeted and intelligent therapies, will be explored. Participation in the webinar is free, but registration is required. We invite everyone to join us for this opportunity for discussion. Knowledge is the first weapon we have to jointly address the challenges this disease presents.